Terms: = Lymphoma AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M AND Treatment
63 results:
1. Evaluation of Immunohistochemical Expression of ALK-1 in Gliomas, WHO Grade 4 and Its Correlation with idh1-R132H Mutation Status.
Khairy RA; Momtaz EM; Abd El Aziz AM; Shibel PEE
Asian Pac J Cancer Prev; 2024 Jan; 25(1):317-323. PubMed ID: 38285799
[TBL] [Abstract] [Full Text] [Related]
2. Comparative evaluation of
Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
[TBL] [Abstract] [Full Text] [Related]
3. Clinical and histological study of follicular helper T-cell lymphomas with indolent evolution.
Messéant O; Drieux F; Sako N; Fataccioli V; Camus V; Robe C; Houot R; Tas P; Llamas-Gutierrez F; Lamaison C; Abraham J; Delage-Corre M; Benguerfi S; Bossard JB; Gaulard P; Lemonnier F
Eur J Cancer; 2024 Jan; 197():113479. PubMed ID: 38128263
[TBL] [Abstract] [Full Text] [Related]
4. treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Sutter T; Schittenhelm M; Volken T; Lehmann T
Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
[TBL] [Abstract] [Full Text] [Related]
5. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and idh inhibitors.
Madero-Marroquin R; DuVall AS; Saygin C; Wang P; Gurbuxani S; Larson RA; Stock W; Patel AA
Br J Haematol; 2024 Apr; 204(4):1238-1242. PubMed ID: 38073116
[TBL] [Abstract] [Full Text] [Related]
6. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
7. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.
Williams LS; Williams KM; Gillis N; Bolton K; Damm F; Deuitch NT; Farhadfar N; Gergis U; Keel SB; Michelis FV; Panch SR; Porter CC; Sucheston-Campbell L; Tamari R; Stefanski HE; Godley LA; Lai C
Transplant Cell Ther; 2024 Mar; 30(3):255-267. PubMed ID: 37913908
[TBL] [Abstract] [Full Text] [Related]
8. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed idh2-mutant AML.
Cai SF; Huang Y; Lance JR; Mao HC; Dunbar AJ; McNulty SN; Druley T; Li Y; Baer MR; Stock W; Kovacsovics T; Blum WG; Schiller GJ; Olin RL; Foran JM; Litzow M; Lin T; Patel P; Foster MC; Boyiadzis M; Collins RH; Chervin J; Shoben A; Vergilio JA; Heerema NA; Rosenberg L; Chen TL; Yocum AO; Druggan F; Marcus S; Stefanos M; Druker BJ; Mims AS; Borate U; Burd A; Byrd JC; Levine RL; Stein EM
Blood Adv; 2024 Jan; 8(2):429-440. PubMed ID: 37871309
[TBL] [Abstract] [Full Text] [Related]
9.
Babakhanlou R; DiNardo C; Borthakur G
Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
[TBL] [Abstract] [Full Text] [Related]
10. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It.
Patel AA; Odenike O
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):303-309. PubMed ID: 36907766
[TBL] [Abstract] [Full Text] [Related]
11. Gene Mutations and Targeted Therapies of Myeloid Sarcoma.
Fu L; Zhang Z; Chen Z; Fu J; Hong P; Feng W
Curr Treat Options Oncol; 2023 Apr; 24(4):338-352. PubMed ID: 36877373
[TBL] [Abstract] [Full Text] [Related]
12. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.
Ruan J; Moskowitz A; Mehta-Shah N; Sokol L; Chen Z; Kotlov N; Nos G; Sorokina M; Maksimov V; Sboner A; Sigouros M; van Besien K; Horwitz S; Rutherford SC; Mulvey E; Revuelta MV; Xiang J; Alonso A; Melnick A; Elemento O; Inghirami G; Leonard JP; Cerchietti L; Martin P
Blood; 2023 May; 141(18):2194-2205. PubMed ID: 36796016
[TBL] [Abstract] [Full Text] [Related]
13. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.
Horbinski C; Nabors LB; Portnow J; Baehring J; Bhatia A; Bloch O; Brem S; Butowski N; Cannon DM; Chao S; Chheda MG; Fabiano AJ; Forsyth P; Gigilio P; Hattangadi-Gluth J; Holdhoff M; Junck L; Kaley T; Merrell R; Mrugala MM; Nagpal S; Nedzi LA; Nevel K; Nghiemphu PL; Parney I; Patel TR; Peters K; Puduvalli VK; Rockhill J; Rusthoven C; Shonka N; Swinnen LJ; Weiss S; Wen PY; Willmarth NE; Bergman MA; Darlow S
J Natl Compr Canc Netw; 2023 Jan; 21(1):12-20. PubMed ID: 36634606
[TBL] [Abstract] [Full Text] [Related]
14. Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing.
Hou Y; Zi J; Liu S; Ge Q; Ge Z
Mol Carcinog; 2023 Feb; 62(2):200-209. PubMed ID: 36300887
[TBL] [Abstract] [Full Text] [Related]
15. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the treatment of idh2- and FLT3-Mutated Acute Myeloid Leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract] [Full Text] [Related]
16. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or idh1/2 inhibitors.
Bewersdorf JP; Shallis RM; Derkach A; Goldberg AD; Stein A; Stein EM; Marcucci G; Zeidan AM; Shimony S; DeAngelo DJ; Stone RM; Aldoss I; Ball BJ; Stahl M
Leuk Lymphoma; 2023 Jan; 64(1):188-196. PubMed ID: 36287540
[TBL] [Abstract] [Full Text] [Related]
17. Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell lymphoma.
Yoon SE; Cho J; Kim YJ; Kim SJ; Kim WS
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e972-e980. PubMed ID: 35995702
[TBL] [Abstract] [Full Text] [Related]
18. Current Considerations in the treatment of Grade 3 Gliomas.
Jo J; Schiff D
Curr Treat Options Oncol; 2022 Sep; 23(9):1219-1232. PubMed ID: 35913658
[TBL] [Abstract] [Full Text] [Related]
19. Epigenetic Aberrations and Targets in Peripheral T-Cell lymphoma.
Atallah-Yunes SA; Robertson MJ; Davé UP
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):659-665. PubMed ID: 35577752
[TBL] [Abstract] [Full Text] [Related]
20. Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell lymphomas.
Kim SJ; Kim YJ; Yoon SE; Ryu KJ; Park B; Park D; Cho D; Kim HY; Cho J; Ko YH; Park WY; Kim WS
Cancer Res Treat; 2023 Jan; 55(1):291-303. PubMed ID: 35240014
[TBL] [Abstract] [Full Text] [Related]
[Next]
